138 related articles for article (PubMed ID: 26058972)
21. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.
Robertson FM; Simeone AM; Mazumdar A; Shah AH; McMurray JS; Ghosh S; Cristofanilli M
J Exp Ther Oncol; 2008; 7(4):299-312. PubMed ID: 19227010
[TBL] [Abstract][Full Text] [Related]
22. Prostaglandin E2 promotes hepatocellular carcinoma cell invasion through upregulation of YB-1 protein expression.
Zhang H; Cheng S; Zhang M; Ma X; Zhang L; Wang Y; Rong R; Ma J; Xia S; Du M; Shi F; Wang J; Yang Q; Bai X; Leng J
Int J Oncol; 2014 Mar; 44(3):769-80. PubMed ID: 24378923
[TBL] [Abstract][Full Text] [Related]
23. EP1- and EP3-receptors mediate prostaglandin E2-induced constriction of porcine large cerebral arteries.
Jadhav V; Jabre A; Lin SZ; Lee TJ
J Cereb Blood Flow Metab; 2004 Dec; 24(12):1305-16. PubMed ID: 15625406
[TBL] [Abstract][Full Text] [Related]
24. Significance of divergent expression of prostaglandin EP4 and EP3 receptors in human prostate cancer.
Huang HF; Shu P; Murphy TF; Aisner S; Fitzhugh VA; Jordan ML
Mol Cancer Res; 2013 Apr; 11(4):427-39. PubMed ID: 23364535
[TBL] [Abstract][Full Text] [Related]
25. Possible involvement of brain prostaglandin E2 and prostanoid EP3 receptors in prostaglandin E2 glycerol ester-induced activation of central sympathetic outflow in the rat.
Shimizu T; Tanaka K; Nakamura K; Taniuchi K; Yawata T; Higashi Y; Ueba T; Dimitriadis F; Shimizu S; Yokotani K; Saito M
Neuropharmacology; 2014 Jul; 82():19-27. PubMed ID: 24657150
[TBL] [Abstract][Full Text] [Related]
26. Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer.
Ke J; Yang Y; Che Q; Jiang F; Wang H; Chen Z; Zhu M; Tong H; Zhang H; Yan X; Wang X; Wang F; Liu Y; Dai C; Wan X
Tumour Biol; 2016 Sep; 37(9):12203-12211. PubMed ID: 27230680
[TBL] [Abstract][Full Text] [Related]
27. Response to tumor necrosis factor-α mediated inflammation involving activation of prostaglandin E2 and Wnt signaling in nucleus pulposus cells.
Hiyama A; Yokoyama K; Nukaga T; Sakai D; Mochida J
J Orthop Res; 2015 Dec; 33(12):1756-68. PubMed ID: 26123748
[TBL] [Abstract][Full Text] [Related]
28. Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation.
Hosono K; Suzuki T; Tamaki H; Sakagami H; Hayashi I; Narumiya S; Alitalo K; Majima M
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1049-58. PubMed ID: 21311040
[TBL] [Abstract][Full Text] [Related]
29. EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
Semmlinger A; von Schoenfeldt V; Wolf V; Meuter A; Kolben TM; Kolben T; Zeder-Goess C; Weis F; Gallwas J; Wuerstlein R; Hermelink K; Schmoeckel E; Harbeck N; Mayr D; Mahner S; Jeschke U; Ditsch N
BMC Cancer; 2018 Apr; 18(1):431. PubMed ID: 29661238
[TBL] [Abstract][Full Text] [Related]
30. Independent down-regulation of EP2 and EP3 subtypes of the prostaglandin E2 receptors on U937 human monocytic cells.
Zeng L; An S; Goetzl EJ
Immunology; 1995 Dec; 86(4):620-8. PubMed ID: 8567030
[TBL] [Abstract][Full Text] [Related]
31. Prostaglandin E2 promotes liver cancer cell growth by the upregulation of FUSE-binding protein 1 expression.
Ma J; Chen M; Xia SK; Shu W; Guo Y; Wang YH; Xu Y; Bai XM; Zhang L; Zhang H; Zhang M; Wang YP; Leng J
Int J Oncol; 2013 Mar; 42(3):1093-104. PubMed ID: 23338277
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effect of prostaglandin E(2) on the migration of nasal fibroblasts.
Shin JM; Park IH; Moon YM; Hong SM; Cho JS; Um JY; Lee HM
Am J Rhinol Allergy; 2014; 28(3):e120-4. PubMed ID: 24980222
[TBL] [Abstract][Full Text] [Related]
33. SGK2 promotes hepatocellular carcinoma progression and mediates GSK-3β/β-catenin signaling in HCC cells.
Liu J; Zhang G; Lv Y; Zhang X; Ying C; Yang S; Kong X; Yu Y
Tumour Biol; 2017 Jun; 39(6):1010428317700408. PubMed ID: 28639896
[TBL] [Abstract][Full Text] [Related]
34. The role of Cox-2 and prostaglandin E
Amior L; Srivastava R; Nano R; Bertuzzi F; Melloul D
FASEB J; 2019 Apr; 33(4):4975-4986. PubMed ID: 30629897
[TBL] [Abstract][Full Text] [Related]
35. In vivo intra-luteal implants of prostaglandin (PG) E1 or E2 (PGE1, PGE2) prevent luteolysis in cows. II: mRNA for PGF2α, EP1, EP2, EP3 (A-D), EP3A, EP3B, EP3C, EP3D, and EP4 prostanoid receptors in luteal tissue.
Weems YS; Bridges PJ; Jeoung M; Arreguin-Arevalo JA; Nett TM; Vann RC; Ford SP; Lewis AW; Neuendorff DA; Welsh TH; Randel RD; Weems CW
Prostaglandins Other Lipid Mediat; 2012 Jan; 97(1-2):60-5. PubMed ID: 22120546
[TBL] [Abstract][Full Text] [Related]
36. PGE
Zang S; Ma X; Wu Y; Liu W; Cheng H; Li J; Liu J; Huang A
Hum Pathol; 2017 May; 63():120-127. PubMed ID: 28300577
[TBL] [Abstract][Full Text] [Related]
37. A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation.
Abrahao AC; Castilho RM; Squarize CH; Molinolo AA; dos Santos-Pinto D; Gutkind JS
Oral Oncol; 2010 Dec; 46(12):880-7. PubMed ID: 20951077
[TBL] [Abstract][Full Text] [Related]
38. Prostaglandin E2 induces stromal cell-derived factor-1 expression in prostate stromal cells by activating protein kinase A and transcription factor Sp1.
Peng Y; Shi J; Du X; Wang L; Klocker H; Mo L; Mo Z; Zhang J
Int J Biochem Cell Biol; 2013 Mar; 45(3):521-30. PubMed ID: 23246486
[TBL] [Abstract][Full Text] [Related]
39. β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma.
Huang GL; Shen DY; Cai CF; Zhang QY; Ren HY; Chen QX
World J Gastroenterol; 2015 Jan; 21(4):1148-57. PubMed ID: 25632187
[TBL] [Abstract][Full Text] [Related]
40. Prostaglandin E2-prostanoid EP3 signal induces vascular contraction via nPKC and ROCK activation in rat mesenteric artery.
Kobayashi K; Murata T; Hori M; Ozaki H
Eur J Pharmacol; 2011 Jun; 660(2-3):375-80. PubMed ID: 21463619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
